Fintel reports that on September 9, 2026, Leerink Partners initiated coverage of Nautilus Biotechnology (NASDAQCM:NAUT) with a Outperform recommendation.

Prior to this rating action, the stock closed at $0.93 on September 8, 2026. This represents a one-week price change of +0.15% from a baseline close of $0.93 on September 1, 2026. Over a one-month period, the stock experienced a price change of +3.09% from a baseline close of $0.90 on August 7, 2026.

Separately, as of August 28, 2026, the current consensus target mean and median for the stock stood at $4.08, representing an implied change of +339.70%. This consensus target remains unchanged from the prior consensus target mean of $4.08 recorded on August 4, 2026, reflecting a revision of 0.00%.

In terms of broader analyst sentiment, the current recommendation period as of September 1, 2026, shows a total of 8 recommendations. This includes 3 strong buy, 4 buy, 1 hold, 0 sell, and 0 strong sell ratings, resulting in a positive recommendation share of 87.5%, a hold share of 12.5%, and a negative share of 0.0%. These figures are identical to the prior recommendation period on August 1, 2026, which also had 8 total recommendations with the same distribution.

On July 28, 2026, Nautilus Biotechnology reported its latest earnings, posting an actual EPS of -0.11, which compared to an estimated EPS of -0.1377. The company's actual revenue for the quarter was reported at $190,000,000,000.00, compared to an estimate of $0.00.

According to the company's EX-99.1 filing dated July 28, 2026, titled "Nautilus Biotechnology Reports Second Quarter 2026 Financial Results," the firm noted that it uses filings with the Securities and Exchange Commission, its website, press releases, public conference calls, public webcasts, and social media accounts to disclose material non-public information and comply with Regulation FD.

Recent analyst actions

Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.

Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.

This story originally appeared on Fintel.